Covidien Expects Continued Growth In Neurovascular Division

With more than $30 million invested in stroke clinical trials and technology, Covidien sees tremendous opportunity in the endovascular treatment of acute ischemic stroke. The company’s ongoing research is laying the foundation for continued growth in its neurovascular division.

The endovascular device market for acute ischemic stroke (AIS) is facing several challenges that could slow market growth, including negative clinical trial results, threats to reimbursement, increasing regulatory requirements, and a challenging funding environment. (See Also see "Stroke Devices: Hope Amid Headwinds" - Medtech Insight, 27 September, 2013..) Despite these headwinds, market leader Medtronic Minimally Invasive Therapies sees opportunity ahead and believes AIS treatments will play a significant role in the future growth of its neurovascular division. According to Brett Wall, president of Covidien’s neurovascular division, who spoke recently with Medtech Insight, there are a number of clinical trials ongoing with Covidien’s Solitaire line of neurothrombectomy devices, and the firm has a strong commitment to the neurointerventional space.

In January 2013 Covidien began enrolling patients in the Solitaire FR as Primary Treatment for Acute Ischemic Stroke (SWIFT PRIME)...

More from Archive

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.